Logo

AbbVie's Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis

Share this

AbbVie's Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis

Shots:

  • The CHMP positive opinion is based on P-III SELECT program including SELECT-NEXT- SELECT-BEYOND- SELECT-MONOTHERAPY- SELECT-COMPARE and SELECT-EARLY assessing Rinvoq in 4-400+ patients with mod. to sev. active RA
  • In P-III studies- Rinvoq improved signs and symptoms of RA- inhibited radiographic progression and improved physical function- both as a monothx. and in combination with conventional synthetic DMARDs
  • Rinvoq is a selective and reversible JAK inhibitor- currently under review with health authorities globally to treat mod. to sev. active RA and being evaluated in P-III studies for multiple immune-mediated inflammatory diseases

Click here to­ read full press release/ article | Ref: AbbVie | Image: AbbVie


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions